CIBC Private Wealth Group LLC Has $48.92 Million Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

CIBC Private Wealth Group LLC decreased its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 2.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 203,368 shares of the biopharmaceutical company's stock after selling 5,118 shares during the period. CIBC Private Wealth Group LLC owned 0.16% of Alnylam Pharmaceuticals worth $48,920,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Jennison Associates LLC bought a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth $61,160,000. Strategic Financial Concepts LLC bought a new stake in Alnylam Pharmaceuticals during the 4th quarter worth about $41,529,000. Truist Financial Corp lifted its position in Alnylam Pharmaceuticals by 136.6% during the 4th quarter. Truist Financial Corp now owns 4,398 shares of the biopharmaceutical company's stock valued at $1,035,000 after purchasing an additional 2,539 shares during the period. Sumitomo Mitsui Trust Group Inc. boosted its stake in shares of Alnylam Pharmaceuticals by 3.0% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 286,703 shares of the biopharmaceutical company's stock valued at $67,464,000 after purchasing an additional 8,462 shares during the last quarter. Finally, Assenagon Asset Management S.A. grew its position in shares of Alnylam Pharmaceuticals by 13.0% during the 4th quarter. Assenagon Asset Management S.A. now owns 19,918 shares of the biopharmaceutical company's stock worth $4,687,000 after buying an additional 2,285 shares during the period. Institutional investors own 92.97% of the company's stock.

Remove Ads

Insider Transactions at Alnylam Pharmaceuticals

In related news, CEO Yvonne Greenstreet sold 1,213 shares of the business's stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $255.17, for a total transaction of $309,521.21. Following the transaction, the chief executive officer now directly owns 81,526 shares of the company's stock, valued at approximately $20,802,989.42. The trade was a 1.47 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 663 shares of the stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $255.21, for a total transaction of $169,204.23. Following the completion of the transaction, the executive vice president now directly owns 14,321 shares in the company, valued at $3,654,862.41. The trade was a 4.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 71,234 shares of company stock worth $19,958,097 in the last 90 days. Corporate insiders own 1.50% of the company's stock.

Alnylam Pharmaceuticals Stock Down 10.1 %

ALNY traded down $26.42 during trading hours on Friday, hitting $235.74. 1,881,579 shares of the company's stock were exchanged, compared to its average volume of 842,696. The stock has a market cap of $30.67 billion, a price-to-earnings ratio of -108.64 and a beta of 0.30. Alnylam Pharmaceuticals, Inc. has a 1-year low of $141.98 and a 1-year high of $304.39. The stock's 50-day moving average is $259.03 and its two-hundred day moving average is $260.33. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.03). Sell-side analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently weighed in on ALNY. Scotiabank increased their price objective on shares of Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the company a "sector outperform" rating in a report on Monday. Royal Bank of Canada lifted their price objective on Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the stock an "outperform" rating in a research note on Friday, March 21st. Bank of America raised their target price on Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the stock a "buy" rating in a report on Friday, March 21st. Wells Fargo & Company increased their price target on shares of Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the company an "equal weight" rating in a research report on Friday, March 21st. Finally, Sanford C. Bernstein cut their target price on shares of Alnylam Pharmaceuticals from $314.00 to $310.00 and set an "outperform" rating on the stock in a report on Tuesday, January 7th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and twenty-one have given a buy rating to the stock. According to MarketBeat, Alnylam Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average price target of $316.25.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.